|
Volumn 116, Issue 1180, 2003, Pages
|
Direct-to-consumer advertising - Where does the public interest lie?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
NEW DRUG;
DRUG;
BUDGET;
DOCTOR PATIENT RELATION;
DRUG COST;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MARKETING;
DRUG SUBSTITUTION;
DRUG SURVEILLANCE PROGRAM;
DRUG UTILIZATION;
EDITORIAL;
GOVERNMENT;
HEALTH CARE ORGANIZATION;
HUMAN;
HUMAN RIGHTS;
MEDICAL DECISION MAKING;
NEW ZEALAND;
PATIENT EDUCATION;
PRESCRIPTION;
PUBLIC HEALTH SERVICE;
RESOURCE ALLOCATION;
ADVERTIZING;
ECONOMICS;
HEALTH INSURANCE;
LEGAL ASPECT;
ADVERTISING;
DRUG INDUSTRY;
INSURANCE, PHARMACEUTICAL SERVICES;
LEGISLATION, DRUG;
NEW ZEALAND;
PHARMACEUTICAL PREPARATIONS;
PRESCRIPTIONS, DRUG;
|
EID: 0642276572
PISSN: 11758716
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
Times cited : (10)
|
References (7)
|